Testicular mixed germ cell tumors: A morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas

Modern Pathology

Volumn 22, Issue 8, 2009, Pages 1066-1074

  Gopalan, Anuradha ^a   Dhall, Deepti ^a   Olgac, Semra ^a   Fine, Samson W ^a   Korkola, James E ^a   Houldsworth, Jane ^a   Chaganti, Raju S ^a   Bosl, George J ^a   Reuter, Victor E ^a   Tickoo, Satish K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

GDF3; Germ cell tumors; OCT3 4; SOX2; Stem cell; Testis

Indexed keywords

CD30 LIGAND; GROWTH DIFFERENTIATION FACTOR 3; GROWTH FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CHORIOCARCINOMA; DIFFERENTIAL DIAGNOSIS; EMBRYONAL CARCINOMA; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MALE; MIXED TUMOR; MORPHOLOGICAL TRAIT; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; TERATOMA; TUMOR CLASSIFICATION; YOLK SAC TUMOR;

GENE EXPRESSION; GENE EXPRESSION PROFILING; GROWTH DIFFERENTIATION FACTOR 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; OCTAMER TRANSCRIPTION FACTOR-3; SOXB1 TRANSCRIPTION FACTORS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 68249119921     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.66     Document Type: Article

References (35)

1. Heidenreich A. Clinical stage I nonseminomatous testicular germ-cell tumors: surgery or watchful waiting, still an issue? Curr Opin Urol 2002;12:427-430.
2. Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000;163:1721-1724.
3. Stephenson AJ, Bosl GJ, Bajorin DF, et al. Retro-peritoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174:557-560.
4. Tickoo SK, Hutchinson B, Bacik J, et al. Testicular seminoma: a clinicopathologic and immunohisto-chemical study of 105 cases with special reference to seminomas with atypical features. Int J Surg Pathol 2002;10:23-32.
5. Hart AH, Hartley L, Parker K, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005;104:2092-2098.
6. Jones TD, Ulbright TM, Eble JN, et al. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol 2004;28:935-940.
7. Tai MH, Chang CC, Kiupel M, et al. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502.
8. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 2007;31:836-845.
9. Korkola JE, Houldsworth J, Chadalavada RS, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006;66:820-827.
10. Skotheim RI, Lind GE, Monni O, et al. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 2005;65:5588-5598.
11. Sperger JM, Chen X, Draper JS, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci USA 2003;100:13350-13355.
12. Rodriguez E, Houldsworth J, Reuter VE, et al. Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes Cancer 1993;8:230-236.
13. Miyagi S, Saito T, Mizutani K, et al. The Sox-2 regulatory regions display their activities in two distinct types of multipotent stem cells. Mol Cell Biol 2004;24:4207-4220.
14. Tomioka M, Nishimoto M, Miyagi S, et al. Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res 2002;30:3202-3213.
15. Yuan H, Corbi N, Basilico C, et al. Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev 1995;19:2635-2645.
16. Episkopou V. SOX2 functions in adult neural stem cells. Trends Neurosci 2005;28:219-221.
17. Catena R, Tiveron C, Ronchi A, et al. Conserved POU binding DNA sites in the Sox2 upstream enhancer regulate gene expression in embryonic and neural stem cells. J Biol Chem 2004;279:41846-41857.
18. Emerson RE, Ulbright TM. The use of immunohisto-chemistry in the differential diagnosis of tumors of the testis and paratestis. Semin Diagn Pathol 2005;22:33-50.
19. Clark AT, Rodriguez RT, Bodnar MS, et al. Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells 2004;22: 169-179.
20. Ulbright TM AM, Young RH. Tumors of the Testis, Adnexa, Spermatic Cord and Scrotum: Atlas of Tumor Pathology. Third Series, Fascicle 25 Armed Forces Institute of Pathology: Washington, DC, 1999.
21. Honecker F, Oosterhuis JW, Mayer F, et al. New insights into the pathology and molecular biology of human germ cell tumors. World J Urol 2004;22:15-24.
22. Honecker F, Stoop H, Mayer F, et al. Germ cell lineage differentiation in non-seminomatous germ cell tumours. J Pathol 2006;208:395-400.
23. Srigley JR, Mackay B, Toth P, et al. The ultrastructure and histogenesis of male germ neoplasia with emphasis on seminoma with early carcinomatous features. Ultrastruct Pathol 1988;12:67-86.
24. Bredael JJ, Vugrin D, Whitmore Jr WF. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 1982;50:548-551.
25. Czaja JT, Ulbright TM. Evidence for the transformation of seminoma to yolk sac tumor, with histogenetic considerations. Am J Clin Pathol 1992;97:468-477.
26. Motzer RJ, Reuter VE, Cordon-Cardo C, et al. Blood group-related antigens in human germ cell tumors. Cancer Res 1988;48:5342-5347.
27. Yuasa T, Yoshiki T, Ogawa O, et al. Detection of alpha-fetoprotein mRNA in seminoma. J Androl 1999; 20:336-340.
28. Donovan PJ. The germ cell - the mother of all stem cells. Int J Dev Biol 1998;42:1043-1050.
29. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126: 663-676.
30. Rathjen J, Lake JA, Bettess MD, et al. Formation of a primitive ectoderm like cell population, EPL cells, from ES cells in response to biologically derived factors. J Cell Sci 1999;112:601-612.
31. Ginsburg M, Snow MH, McLaren A. Primordial germ cells in the mouse embryo during gastrulation. Development 1990;110:521-528.
32. Berney DM, Shamash J, Pieroni K, et al. Loss of CD30 expression in metastatic embryonal carcinoma: the effects of chemotherapy? Histopathology 2001;39: 382-385.
33. Sung MT, Jones TD, Beck SD, et al. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Hum Pathol 2006; 37:662-667.
34. Caricasole AA, van Schaik RH, Zeinstra LM, et al. Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. Oncogene 1998;16:95-103.
35. Jones CM, Simon-Chazottes D, Guenet JL, et al. Isolation of Vgr-2, a novel member of the transforming growth factor-beta-related gene family. Mol Endocrinol 1992;6:1961-1968.